Skip to main content

Share story

Products

D-Wave Quantum scheduled to report Q4 and FY2025 results

D-Wave Quantum Inc. announced it will release its financial results for the fourth quarter and fiscal year 2025 ended December 31, 2025, on Thursday, February 26, 2026, before market open. The press release will be available on the D-Wave Investor Relations website. The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the financial results and business outlook. The live dial-in number is 1-844-826-3035 for domestic participants or 1-412-317-5195 for international callers. Participants can use those numbers or a link for instant telephone access that activates 15 minutes prior to the start time with passcode 3836181. Chief Executive Officer Dr. Alan Baratz and Chief Financial Officer John Markovich will participate in the call. An on-demand webcast will be available, and a transcript of the conference call will be posted on the D-Wave Investor Relations website after the call.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from D-Wave and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.